OpenAI Researcher Miles Wang in Talks to Launch AI Drug Discovery Startup Valued at $2B

OpenAI researcher Miles Wang is in advanced talks to launch an AI-focused drug discovery startup that is reportedly valued at $2 billion, according to sources familiar with the matter cited by TechCrunch. Wang is said to be in deep negotiations with multiple venture capital firms to build a company that leverages AI to accelerate pharmaceutical research.

Wang, currently a researcher at OpenAI, brings deep expertise in artificial intelligence to the venture, which has attracted top-tier investor attention even before its formal launch. The reported $2 billion valuation places it among the most highly valued AI biotech startups in the current market.

The AI drug discovery sector has grown rapidly in recent years, with numerous startups using large language models and generative AI to predict molecular structures, screen drug candidates, and optimize clinical trial designs. Wang's planned company would bring OpenAI's frontier AI techniques to bear on these challenges.

AI-driven drug discovery promises to dramatically shorten traditional drug development timelines — compressing what typically takes over a decade into just a few years — while reducing the billions of dollars in R&D costs. However, the field continues to face significant hurdles in clinical validation and regulatory approval.

Wang has not yet publicly disclosed the startup's specific research direction, technical approach, or official name. Sources caution that the funding discussions remain ongoing, and the final valuation and investor lineup could still shift.

This move follows a broader pattern of OpenAI researchers departing to found their own ventures, spanning domains from general-purpose AI to specialized vertical applications. Wang's focus on life sciences represents a pivot toward high-social-impact verticals.

Key developments to watch include the company's technical differentiation strategy and its initial pharmaceutical partnerships, which will determine whether it can carve out a competitive edge in the increasingly crowded AI drug discovery space.